Immunocore To Tap HTA Advice To Ensure IMCgp100 Success
This article was originally published in Scrip
British immunotherapy specialist Immunocore Limited plans to make full use of the scientific advice national regulators are offering to help it progress its lead product IMCgp100 through the European Medicines Agency's adaptive pathways pilot program.
You may also be interested in...
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.
Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.